Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:13 2026-05-18 am EDT			5-day change	1st Jan Change
117.20 ^CHF	+0.45%		+3.08%	+6.93%

May. 18	Top Midday Stories: NextEra, Dominion to Combine in All-Stock Deal; Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 18	Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT

NOVARTIS AG : Goldman Sachs remains a Sell rating

Published on 03/31/2026 at 05:15 am EDT

MarketScreener with dpa-AFX Analyser

NOVARTIS AG

+0.45%

James Quigley from Goldman Sachs retains his negative opinion on the stock with a Sell rating. The target price is increased from CHF 101 to CHF 105.

Latest news about Novartis AG

May. 18	Top Midday Stories: NextEra, Dominion to Combine in All-Stock Deal; Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 18	Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 18	Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case	MT
May. 18	US Supreme Court rebuffs pharma challenge to Biden-era drug price	RE
May. 18	Novartis Says Prostate Cancer Treatment Lowers Progression Risk By 58%	MT
May. 18	Novartis - Data shows 58% lower risk of PSA progression with Pluvicto in prostate cancer	RE
May. 17	Novartis : New PSMAddition data show 58% lower risk of PSA progression with Pluvicto(R) in metastatic hormone-sensitive prostate cancer	DJ
May. 15	Health Rounds: Common ADHD medicines help treat cancer-related fatigue	RE
May. 13	Wall Street Just Got Its Wholesale Receipt
May. 13	Inflation weighs on the mood
May. 11	Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence	DJ
May. 08	A lot of noise, little impact?
May. 08	Much ado about nothing?
May. 07	Novartis Starts Construction on Texas Cancer Therapy Manufacturing Facility	MT
May. 07	Novartis AG - Denton site expected to be operational in 2028 and create new US jobs	RE

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company